APP-FUBINACA
APP-FUBINACA[edit | edit source]
APP-FUBINACA is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of a class of compounds that are often used in the production of designer drugs and are sometimes found in products marketed as "synthetic cannabis".
Chemical Properties[edit | edit source]
APP-FUBINACA is chemically classified as an indazole-based synthetic cannabinoid. It is structurally related to other synthetic cannabinoids such as AB-FUBINACA and ADB-FUBINACA. The compound is known for its high affinity and efficacy at the CB1 receptor, which is primarily responsible for the psychoactive effects associated with cannabinoids.
Pharmacology[edit | edit source]
APP-FUBINACA acts as a full agonist at the CB1 receptor and CB2 receptor, with a higher affinity for the CB1 receptor. This interaction leads to the activation of the endocannabinoid system, resulting in effects that mimic those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Effects[edit | edit source]
The effects of APP-FUBINACA can include euphoria, relaxation, altered perception, and increased appetite. However, due to its potency, it can also cause adverse effects such as anxiety, paranoia, tachycardia, and in severe cases, psychosis or seizures.
Legal Status[edit | edit source]
Due to its potential for abuse and lack of medical use, APP-FUBINACA is classified as a controlled substance in many countries. It is often included in legislation targeting synthetic cannabinoids and other new psychoactive substances (NPS).
Synthesis[edit | edit source]
The synthesis of APP-FUBINACA involves the reaction of an indazole core with a fluorobenzyl group and a carboxamide moiety. The process requires specialized knowledge in organic chemistry and access to controlled precursors.
Health Risks[edit | edit source]
The use of APP-FUBINACA is associated with significant health risks. Overdose can lead to severe cardiovascular and neurological complications. Long-term use may result in addiction and cognitive impairment.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
